Clinigen Group opens Global Operations Centre

Published: 14-Mar-2012
Pharmaceutical

Will improve distribution and stock levels

Clinigen Group opens Global Operations Centre
Clinigen Group, a global specialist pharmaceutical products and services business based in the UK, has opened a new £350,000 Global Operations Centre in Stretton, near Burton-on-Trent Staffordshire.

Peter George, chief executive of Clinigen, said: ‘We are continuing to expand and have ambitious plans for the future. It is essential that we have the right resource and facilities to service our clients, both now, and as we continue to develop.’

The firm says the new 8,000ft2 warehousing and distribution facilities will enable it to stock and distribute pharmaceutical products to its global customer base in a fast and efficient manner.

The new Operations Centre combined with the company's headquarters in Burton, have created more than 30 new jobs in recent months. In total the firm employs 300 staff.

Clinigen Group was formed in 2010 by the merger of three companies: Clinigen CTS (formerly Keats Healthcare) and Clinigen GAP, which make up Clinigen's services division, and Clinigen Healthcare, the Group's products business.

The Group operates across the clinical lifecycle of a drug, from Phase 1 clinical trials to the end of patent and beyond.

See more

You may also like

Distribution
Santhera and Clinigen partner to distribute DMD treatment AGAMREE to eligible patients globally

Santhera and Clinigen partner to distribute DMD treatment AGAMREE to eligible patients globally

Read more
Clinigen Group will be respsonsible for the distribution of Duchenne muscular dystrophy (DMD) treatment AGAMREE (vamorolone) in regions not currently covered by Santhera or its distribution partners

Trending Articles

  1. Piramal Pharma receives Ontario investment for API site Piramal Pharma Solutions (PPS) is to invest more than $5.3m in upgrading its drug substance manufacturing site in Aurora, Canada, supported by a $1.75m investment from the Ontario government
  2. Biosynth expands complex chemistry portfolio for biologics and vaccines The expansion includes new fluorinated sugars and GMP-grade Poly(I:C), supporting glycoengineering, bioproduction, vaccine and immunotherapy development
  3. Schreiner MediPharm to present new multifunctional label for pens and autoinjectors at CPHI Milan 2026 Booming markets for GLP-1 drugs pose special challenges to pharmaceutical manufacturers. For this purpose, Schreiner MediPharm, a leading developer and manufacturer of innovative functional labels for the healthcare industry, has developed a new multifunctional label for pens and autoinjectors combining analog and digital security features with additional benefits. Schreiner MediPharm will be presenting the label at CPHI Milan from October 6 to 8, 2026 at Booth 11F61
  4. Piramal Pharma Solutions and NP2 to complete cyclophosphamide development phase next month Piramal Pharma Solutions (“PPS”), a leading global Contract Development and Manufacturing Organisation (CDMO) and part of Piramal Pharma Ltd. (“PPL”) (NSE: PPLPHARMA | BSE: 543635), and its partner NP2, a nonprofit generic drug manufacturer, today announced their plans to finish the drug development phase of the generic cancer drug cyclophosphamide in October
  5. FUJIFILM Biotechnologies lands three CPHI Pharma Award nominations for continuous manufacturing and precision purification The CDMO's MaruX platform, ShunzymeX purification technology and COO Maja Pedersen are all shortlisted ahead of its CPHI Milan appearance at booth 8A2, where senior leadership will present on Europe's biomanufacturing strategy

You may also like

Distribution
Santhera and Clinigen partner to distribute DMD treatment AGAMREE to eligible patients globally

Santhera and Clinigen partner to distribute DMD treatment AGAMREE to eligible patients globally

Clinigen Group will be respsonsible for the distribution of Duchenne muscular dystrophy (DMD) treatment AGAMREE (vamorolone) in regions not currently covered by Santhera or its distribution partners
Packaging
Packaging for success

Packaging for success

Somewhat misguidedly, pharmaceutical packaging is often overlooked or assumed to be a commodity service that “anyone can do,” says Scott Houlton, CEO, CSM (a Clinigen Group company)
Finance

Clinigen’s £225m acquisition of Idis goes ahead

Acquisition accelerates the company's growth, provides a better balanced portfolio and extends its business model
Finance

2014 Sunday Times Rich List sees entry of more pharma executives

Ernesto and Kirsty Bertarelli are still out ahead of the rest
Design & Build
Agilent expands Boulder facility with dedicated enzymatic ligation laboratory for oligonucleotide therapeutics

Agilent expands Boulder facility with dedicated enzymatic ligation laboratory for oligonucleotide therapeutics

The new space complements established solid-phase synthesis operations, giving Agilent's Advanced Therapeutics Division a dedicated environment to develop solvent-free enzymatic manufacturing approaches as oligonucleotide pipeline demand grows
Finance
Piramal Pharma receives Ontario investment for API site

Piramal Pharma receives Ontario investment for API site

Piramal Pharma Solutions (PPS) is to invest more than $5.3m in upgrading its drug substance manufacturing site in Aurora, Canada, supported by a $1.75m investment from the Ontario government
Manufacturing
Piramal Pharma Solutions and NP2 to complete cyclophosphamide development phase next month

Piramal Pharma Solutions and NP2 to complete cyclophosphamide development phase next month

Piramal Pharma Solutions (“PPS”), a leading global Contract Development and Manufacturing Organisation (CDMO) and part of Piramal Pharma Ltd. (“PPL”) (NSE: PPLPHARMA | BSE: 543635), and its partner NP2, a nonprofit generic drug manufacturer, today announced their plans to finish the drug development phase of the generic cancer drug cyclophosphamide in October
Subscribe now